Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Introduction

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1)

- The report reviews Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

• Table of Contents

  Table of Contents 2

  List of Tables 7

  List of Figures 8

  Introduction 9

  Global Markets Direct Report Coverage 9

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Overview 10

  Therapeutics Development 11

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Stage of Development 11

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Therapy Area 12

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Indication 13

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Products Glance 16

  Late Stage Products 16

  Early Stage Products 17

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Companies 18

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Universities/Institutes 30

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Therapeutics Assessment 32

  Assessment by Monotherapy/Combination Products 32

  Assessment by Mechanism of Action 33

  Assessment by Route of Administration 35

  Assessment by Molecule Type 37

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 39

  AB Science SA 39

  Advenchen Laboratories, LLC 41

  Amgen Inc. 42

  ArQule, Inc. 43

  Ascendis Pharma A/S 44

  Astellas Pharma Inc. 45

  AstraZeneca Plc 46

  AVEO Pharmaceuticals, Inc. 47

  Bayer AG 48

  Boehringer Ingelheim GmbH 49

  Bristol-Myers Squibb Company 50

  CASI Pharmaceuticals Inc. 51

  Celon Pharma Sp. z o.o. 52

  Debiopharm International SA 53

  Eddingpharm 54

  Eisai Co., Ltd. 55

  Eli Lilly and Company 57

  Hutchison MediPharma Limited 58

  Incyte Corporation 59

  Johnson & Johnson 60

  Les Laboratoires Servier SAS 61

  Merck KGaA 62

  Novartis AG 63

  Principia Biopharma Inc. 64

  Vichem Chemie Research Ltd. 65

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Drug Profiles 66

  ARQ-087 - Drug Profile 66

  Product Description 66

  Mechanism Of Action 66

  R&D Progress 66

  ASP-5878 - Drug Profile 68

  Product Description 68

  Mechanism Of Action 68

  R&D Progress 68

  AV-370 - Drug Profile 69

  Product Description 69

  Mechanism Of Action 69

  R&D Progress 69

  AZD-4547 - Drug Profile 70

  Product Description 70

  Mechanism Of Action 70

  R&D Progress 70

  B-701 - Drug Profile 72

  Product Description 72

  Mechanism Of Action 72

  R&D Progress 72

  BAY-1163877 - Drug Profile 73

  Product Description 73

  Mechanism Of Action 73

  R&D Progress 73

  BMS-986036 - Drug Profile 74

  Product Description 74

  Mechanism Of Action 74

  R&D Progress 74

  CPL-043 - Drug Profile 75

  Product Description 75

  Mechanism Of Action 75

  R&D Progress 75

  Debio-1347 - Drug Profile 76

  Product Description 76

  Mechanism Of Action 76

  R&D Progress 76

  E-7090 - Drug Profile 78

  Product Description 78

  Mechanism Of Action 78

  R&D Progress 78

  EDP-317 - Drug Profile 79

  Product Description 79

  Mechanism Of Action 79

  R&D Progress 79

  ENMD-2076 - Drug Profile 80

  Product Description 80

  Mechanism Of Action 80

  R&D Progress 80

  erdafitinib - Drug Profile 85

  Product Description 85

  Mechanism Of Action 85

  R&D Progress 85

  HMPL-453 - Drug Profile 87

  Product Description 87

  Mechanism Of Action 87

  R&D Progress 87

  INCB-54828 - Drug Profile 88

  Product Description 88

  Mechanism Of Action 88

  R&D Progress 88

  infigratinib - Drug Profile 89

  Product Description 89

  Mechanism Of Action 89

  R&D Progress 89

  lenvatinib mesylate - Drug Profile 91

  Product Description 91

  Mechanism Of Action 91

  R&D Progress 91

  lucitanib - Drug Profile 104

  Product Description 104

  Mechanism Of Action 104

  R&D Progress 104

  LY-2874455 - Drug Profile 107

  Product Description 107

  Mechanism Of Action 107

  R&D Progress 107

  masitinib - Drug Profile 108

  Product Description 108

  Mechanism Of Action 108

  R&D Progress 108

  nintedanib - Drug Profile 121

  Product Description 121

  Mechanism Of Action 121

  R&D Progress 121

  pazopanib hydrochloride - Drug Profile 130

  Product Description 130

  Mechanism Of Action 130

  R&D Progress 130

  pazopanib hydrochloride + pembrolizumab - Drug Profile 137

  Product Description 137

  Mechanism Of Action 137

  R&D Progress 137

  PRN-1371 - Drug Profile 138

  Product Description 138

  Mechanism Of Action 138

  R&D Progress 138

  Recombinant Peptide to Antagonize FGFR3 for Achondroplasia - Drug Profile 139

  Product Description 139

  Mechanism Of Action 139

  R&D Progress 139

  Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 140

  Product Description 140

  Mechanism Of Action 140

  R&D Progress 140

  Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 141

  Product Description 141

  Mechanism Of Action 141

  R&D Progress 141

  S-49076 - Drug Profile 142

  Product Description 142

  Mechanism Of Action 142

  R&D Progress 142

  Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 143

  Product Description 143

  Mechanism Of Action 143

  R&D Progress 143

  sprifermin - Drug Profile 144

  Product Description 144

  Mechanism Of Action 144

  R&D Progress 144

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Dormant Projects 146

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Discontinued Products 151

  Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Featured News & Press Releases 153

  Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product 153

  Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 153

  Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 154

  Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung 156

  Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland 157

  Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 159

  Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 159

  Oct 03, 2016: AB Science has been invited at four international meetings to present new preclinical data showing neuroprotective effect of masitinib in amyotrophic lateral sclerosis (ALS) 160

  Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma 162

  Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016 163

  Sep 29, 2016: AB Science Announces the Filing of Masitinib in the Treatment of Amyotrophic Lateral Sclerosis (ALS) to the European Medicines Agency 164

  Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 165

  Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association 165

  Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 166

  Sep 15, 2016: ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal 167

  Appendix 168

  Methodology 168

  Coverage 168

  Secondary Research 168

  Primary Research 168

  Expert Panel Validation 168

  Contact Us 168

  Disclaimer 169

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

32495 | GMDHC0670TDB

Number of Pages

169

Report Format

PDF

Related Reports